The company has earned net profit of INR4.43bn, resulting into a net margin of 30%.
The company has posted net sales of INR57.21bn for the financial year ended 31 March 2011, an increase of 43% over FY 2010.
The growth in sales is primarily on account of Taro financials that have been consolidated for a little over 6 months in FY11 financials though not included in corresponding periods of the previous year.
Sun Pharma has earned net profit of INR18.16bn, resulting into a net margin of 32%.
Sun Pharmaceutical Industries intends to make an investment of around INR4.50bn to expand and upgrade its existing plants, which also includes Taro facilities.
Sun Pharma chairman and managing director Dilip Shanghvi said Taro acquisition has enhanced their presence in the US market, a key objective of long term strategy, even as they continue to file new products on their own and evaluate further acquisition opportunities.
"Our long term joint venture with MSD for the Emerging Markets underscores the strategic importance of these markets for our business," Shanghvi said.